Novel Immunotherapy Approaches in AML: Focus on Monoclonal Antibodies

Monoclonal antibody (mAb)-based therapies have become an important modality for cancer treatment but have had limited success to date in acute myeloid leukemia (AML). Identification of new antigenic targets and antibody engineering techniques may overcome the modest anti-leukemic effects seen with most native antibodies studied previously in AML. Advances in bispecific immune-engaging antibody technology may improve the pharmacology of these agents, and the safety and efficacy of antibody-drug conjugates (ADCs) may be enhanced by better cytotoxic payloads and chemical linkers.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research